Download presentation
Published byMagdalene Barton Modified over 8 years ago
1
Presented By Michael Overman at 2016 ASCO Annual Meeting
Nivolumab ± Ipilimumab in Treatment of Patients With Metastatic Colorectal Cancer With and Without High Microsatellite Instability: <br />CheckMate 142 Interim Results Presented By Michael Overman at 2016 ASCO Annual Meeting
2
Presented By Michael Overman at 2016 ASCO Annual Meeting
Disclosure Presented By Michael Overman at 2016 ASCO Annual Meeting
3
Introduction<br />Nivolumab ± Ipilimumab in Metastatic CRC
Presented By Michael Overman at 2016 ASCO Annual Meeting
4
Presented By Michael Overman at 2016 ASCO Annual Meeting
Hypermutation and Immuno-Oncology:<br />Rationale for Evaluating Nivolumab ± Ipilimumab in CRC Presented By Michael Overman at 2016 ASCO Annual Meeting
5
Ipilimumab and Nivolumab <br />Mechanisms of Action
Presented By Michael Overman at 2016 ASCO Annual Meeting
6
Presented By Michael Overman at 2016 ASCO Annual Meeting
Eligibility Criteria<br />Nivolumab ± Ipilimumab in Metastatic CRC Presented By Michael Overman at 2016 ASCO Annual Meeting
7
Phase 2 CheckMate 142 Study Design: Microsatellite Stable (MSS) Cohort
Presented By Michael Overman at 2016 ASCO Annual Meeting
8
Phase 2 CheckMate 142 Study Design: <br />MSI-H Cohort
Presented By Michael Overman at 2016 ASCO Annual Meeting
9
Study Endpoints<br />Nivolumab ± Ipilimumab in Metastatic CRC
Presented By Michael Overman at 2016 ASCO Annual Meeting
10
Demographics<br />Nivolumab ± Ipilimumab in Metastatic CRC
Presented By Michael Overman at 2016 ASCO Annual Meeting
11
Presented By Michael Overman at 2016 ASCO Annual Meeting
Disease Characteristics and Prior Therapy<br />Nivolumab ± Ipilimumab in Metastatic CRC Presented By Michael Overman at 2016 ASCO Annual Meeting
12
Presented By Michael Overman at 2016 ASCO Annual Meeting
MSI-H Patient Disposition<br />Nivolumab ± Ipilimumab in Metastatic CRC Presented By Michael Overman at 2016 ASCO Annual Meeting
13
Presented By Michael Overman at 2016 ASCO Annual Meeting
Investigator-Assessed Best Overall Response in <br />Patients With MSI-H Receiving Nivolumab Monotherapy Presented By Michael Overman at 2016 ASCO Annual Meeting
14
Presented By Michael Overman at 2016 ASCO Annual Meeting
Investigator-Assessed Best Overall Response in <br />Patients With MSI-H Receiving Nivolumab + Ipilimumab Presented By Michael Overman at 2016 ASCO Annual Meeting
15
Presented By Michael Overman at 2016 ASCO Annual Meeting
Best Reduction in Target Lesion Size <br />in Patients With MSI-H Presented By Michael Overman at 2016 ASCO Annual Meeting
16
Presented By Michael Overman at 2016 ASCO Annual Meeting
Investigator-Assessed PFS in Patients With MSI-H<br />Nivolumab ± Ipilimumab in Metastatic CRC Presented By Michael Overman at 2016 ASCO Annual Meeting
17
Presented By Michael Overman at 2016 ASCO Annual Meeting
OS in Patients With MSI-H<br />Nivolumab ± Ipilimumab in Metastatic CRC Presented By Michael Overman at 2016 ASCO Annual Meeting
18
Presented By Michael Overman at 2016 ASCO Annual Meeting
<br />Summary of Efficacy in Patients With MSS<br />Nivolumab ± Ipilimumab in Metastatic CRC Presented By Michael Overman at 2016 ASCO Annual Meeting
19
Presented By Michael Overman at 2016 ASCO Annual Meeting
Treatment-Related Adverse Events <br />in ≥ 15% of Patients With MSI-H Presented By Michael Overman at 2016 ASCO Annual Meeting
20
Presented By Michael Overman at 2016 ASCO Annual Meeting
Treatment-Related Adverse Events <br />in ≥ 15% of Patients With MSS Presented By Michael Overman at 2016 ASCO Annual Meeting
21
Conclusions<br />Nivolumab ± Ipilimumab in Metastatic CRC
Presented By Michael Overman at 2016 ASCO Annual Meeting
22
Presented By Michael Overman at 2016 ASCO Annual Meeting
Acknowledgments Presented By Michael Overman at 2016 ASCO Annual Meeting
23
CheckMate 142 Investigators
Presented By Michael Overman at 2016 ASCO Annual Meeting
Similar presentations
© 2024 SlidePlayer.com. Inc.
All rights reserved.